ROCKVILLE, Md., Jan. 30, 2008 (PRIME NEWSWIRE) -- Cytomedix, Inc. (AMEX:GTF) today announced that its public comment, submitted in response to the Centers for Medicare and Medicaid Services' (CMS) proposed decision memorandum (PDM), is now available at CMS' website. A copy of the full comment is available via the link below. CMS has preliminarily proposed not to change its existing 2003 National Coverage Decision which includes non-covered Autologous Blood-Derived Products for Chronic Non-Healing Wounds, such as AutoloGel. CMS has stated that a public comment period on the PDM ended on January 19, 2008, with a final decision expected to be issued by March 19, 2008.
